{"id":21111,"date":"2025-01-09T22:41:11","date_gmt":"2025-01-09T14:41:11","guid":{"rendered":"https:\/\/flcube.com\/?p=21111"},"modified":"2025-01-09T22:41:13","modified_gmt":"2025-01-09T14:41:13","slug":"china-medical-system-licenses-alpha-cognitions-zunveyl-for-dementia-treatment-in-asia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21111","title":{"rendered":"China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia"},"content":{"rendered":"\n

China Medical System Holdings (CMS; HKG: 0867<\/a>) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer’s disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.<\/p>\n\n\n\n

Zunveyl: Next-Generation AChEI<\/strong>
Zunveyl is a next-generation acetylcholinesterase inhibitor (AChEI) approved in the US in July of last year. It improves cognitive and memory function in Alzheimer’s disease patients by inhibiting acetylcholinesterase activity and increasing central acetylcholine levels. As a prodrug of galantamine, Zunveyl passes through the stomach and intestines in an inert form, metabolizes into active ingredients in the liver, and is released into the bloodstream. This mechanism of action allows for the same therapeutic effect as galantamine, with reduced gastrointestinal adverse reactions and improved tolerance.<\/p>\n\n\n\n

Significance of the License Agreement<\/strong>
The license agreement between CMS Holdings and Alpha Cognition highlights the growing interest in innovative treatments for Alzheimer’s disease. By securing the rights to Zunveyl, CMS aims to expand its portfolio of neurological therapies and provide patients in Asia, Australia, and New Zealand with access to this next-generation AChEI. This development underscores the commitment of both companies to improving patient outcomes and addressing the significant unmet need in dementia treatment.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition…<\/p>\n","protected":false},"author":1,"featured_media":21113,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3102,325,844],"class_list":["post-21111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alpha-cognition","tag-china-medical-system","tag-hkg-0867"],"yoast_head":"\nChina Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer's disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21111\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer's disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21111\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T14:41:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T14:41:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"591\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia\",\"datePublished\":\"2025-01-09T14:41:11+00:00\",\"dateModified\":\"2025-01-09T14:41:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111\"},\"wordCount\":262,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0919.png\",\"keywords\":[\"Alpha Cognition\",\"China Medical System\",\"HKG: 0867\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21111#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21111\",\"name\":\"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0919.png\",\"datePublished\":\"2025-01-09T14:41:11+00:00\",\"dateModified\":\"2025-01-09T14:41:13+00:00\",\"description\":\"China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer's disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21111\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0919.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0919.png\",\"width\":1080,\"height\":591,\"caption\":\"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21111#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia - Insight, China's Pharmaceutical Industry","description":"China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer's disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21111","og_locale":"en_US","og_type":"article","og_title":"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia","og_description":"China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer's disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.","og_url":"https:\/\/flcube.com\/?p=21111","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T14:41:11+00:00","article_modified_time":"2025-01-09T14:41:13+00:00","og_image":[{"width":1080,"height":591,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21111#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21111"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia","datePublished":"2025-01-09T14:41:11+00:00","dateModified":"2025-01-09T14:41:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21111"},"wordCount":262,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png","keywords":["Alpha Cognition","China Medical System","HKG: 0867"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21111#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21111","url":"https:\/\/flcube.com\/?p=21111","name":"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21111#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png","datePublished":"2025-01-09T14:41:11+00:00","dateModified":"2025-01-09T14:41:13+00:00","description":"China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer's disease (AD) and is approved for the said indication in the US. The agreement covers Asia (excluding Japan), Australia, and New Zealand, with Alpha retaining the manufacturing supply rights in these territories. No financial details were disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21111#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21111"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21111#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png","width":1080,"height":591,"caption":"China Medical System Licenses Alpha Cognition's Zunveyl for Dementia Treatment in Asia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21111#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0919.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21111"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21111\/revisions"}],"predecessor-version":[{"id":21114,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21111\/revisions\/21114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21113"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}